NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.

摘要: NAD(P)H:Quinone oxidoreductase-1 (NQO1) has been implicated in the bioreductive activation of clinically active anticancer drug Mitomycin C (MMC) and a polymorphic variant NQO1 which lacks functional enzyme activity (NQO1*2) linked with poor survival patients treated MMC. The relationship between cellular response to MMC is however controversial aim this study was determine whether bladder cancer can be forecast on basis NQO1*2 genotype status. Genomic DNA extracted from formalin-fixed, paraffin-embedded tissue 148 low intermediate grade (G1/G2) superficial (Ta/T1) cancers status determined by PCR-RFLP. retrospectively compared clinical intravesical administered primary end-point being time first recurrence. phenotype immunohistochemistry. Of genotyped, 85 (57.4%) were NQO1*1 (wild-type), 59 (39.8%) NQO1*1/*2 (heterozygotes) 4 (2.7%) NQO1*2/*2. No protein expression detected NQO1*2/*2 tumours. A broad spectrum existed tumours genotyped as although typically expressed higher protein. correlation results retrospective suggest that tailoring therapy individual unlikely benefit.